Delgocitinib is a Janus kinase (JAK) inhibitor used to treat atopic dermatitis [1]. While a precise PNG image of its structure is not directly available within the provided text, the drug's chemical name is 3-({4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]phenyl}amino)propanenitrile [1]. This chemical name describes the molecular arrangement of delgocitinib.
What are Janus kinase (JAK) inhibitors?
Janus kinase (JAK) inhibitors are a class of medications that target specific enzymes in the body's immune system [2]. These enzymes, known as Janus kinases, play a role in signaling pathways that can lead to inflammation [2]. By blocking JAK enzymes, these drugs can help reduce inflammation associated with certain autoimmune and inflammatory conditions [2]. Delgocitinib is one such JAK inhibitor [1].
How does delgocitinib work?
Delgocitinib functions by inhibiting Janus kinases (JAKs) [1]. This inhibition interferes with the signaling pathways that promote inflammation and immune responses [1]. In the context of atopic dermatitis, this mechanism helps to alleviate the inflammatory processes contributing to the condition [1].
Where can I find more information on drug patents?
For comprehensive information on drug patents, including timelines and potential exclusivity periods, DrugPatentWatch.com is a valuable resource [3]. This site provides data and analysis on drug patents, which can be crucial for understanding market entry for generic or biosimilar versions of medications [3].